According to a recent LinkedIn post from Xeltis, the company’s aXess hemodialysis conduit was a focal point at the joint conference of the Italian Society of Nephrology’s Vascular Access Project Group and the Vascular Access Society Italian Chapter. The post reports strong clinician interest in presentations covering 12‑month pivotal study data and real‑world outcomes from 24 patients at Policlinico of Bari.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post notes that a poster on Xeltis’ bioresorbable aXess conduits received a “Best Poster Award,” with results described as infection‑free access and high patency compared with ePTFE grafts at the same center. While detailed data are not provided, the recognition and engagement at a specialized vascular access meeting suggest growing clinical momentum that could support future reimbursement discussions and market adoption.
For investors, the post implies that Xeltis is progressing its pivotal study program in hemodialysis access, a segment where complications and infections remain a significant cost and clinical burden. If pivotal results continue to compare favorably versus established grafts, Xeltis could strengthen its positioning in renal care devices and potentially broaden its addressable market in vascular access.
The emphasis on collaboration with leading Italian nephrology and vascular access centers also points to an expanding network of key opinion leaders, which may be important for future commercialization. However, the information remains early‑stage and promotional in nature, and investors would likely require peer‑reviewed data, regulatory milestones, and commercialization updates to better assess the company’s revenue potential and competitive durability.